Targeted Radiotherapies for Patients with Unmet Needs

Actinium is developing a pipeline of Antibody Radiation Conjugates for targeted conditioning and combination therapies

The Pivotal Phase 3 SIERRA Trial for Iomab-B is 100% Enrolled.

Learn More

Email Sign Up

Receive the latest news, events and updates!

Sign Up Now